Resveratrol and Exercise to Treat Functional Limitations in Late Life

Aging Clinical Trial

Official title:

Resveratrol and Exercise to Treat Functional Limitations in Late Life

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02523274
• Other study ID #: IRB201500598 -N
• Secondary ID: R21AG049974
• Status: Completed
• Phase: Phase 2
• Start date: June 2016
• Est. completion date: July 17, 2019

Study information

• Verified date: December 2021
• Source: University of Florida
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this research study is to evaluate the effects of combining physical exercise with a resveratrol supplementation on the physical function of older adults.

Description:

This investigation is a pilot study to investigate the potential of resveratrol, a commercially-available nutritional product, to enhance the efficacy of physical exercise in improving physical function among older adults with functional limitations. The overarching objective of this project is to evaluate the safety and efficacy of an intervention combining resveratrol supplementation and physical exercise among sedentary persons aged > 65 years objectively-measured functional impairments. A total of 60 participants will be recruited to participate in this three month intervention study. All participants will engage in a center-based exercise program 3/days per week and will be randomly assigned to consume 1) placebo, 2) 500 mg/day resveratrol, or 3) 1000 mg/day resveratrol. This study will provide critical information regarding the influence of the combination of resveratrol and exercise on objectively-measured and self-assessed indices of physical function. The study will also provide novel biologic information regarding the relative effects of the interventions on skeletal muscle mitochondrial function.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: July 17, 2019
• Est. primary completion date: May 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 65 Years and older

Eligibility

Inclusion Criteria:

• Ability to understand study procedures and to comply with them for the entire length of the study

• Willingness to be randomized into either treatment group

• Age 65 years and older

• Physical limitations evidenced by >290 seconds needed to complete long-distance corridor walk test

• Sedentary lifestyle, defined as <150 min/wk of moderate physical activity as assessed by CHAMPS questionnaire

Exclusion Criteria:

• Failure to provide informed consent

• Regular consumption of a resveratrol supplement

• Current involvement in supervised rehabilitation program

• Absolute contraindication(s) to exercise training according to American College of Sports Medicine guidelines

• Pain classification > Grade 3 on Graded Chronic Pain Scale

• Peripheral vascular disease; peripheral neuropathy; retinopathy

• Severe cardiac disease, including:

NYHA Class III or IV congestive heart failure, clinically significant aortic stenosis, history of cardiac arrest, use of a cardiac defibrillator, or uncontrolled angina

• Myocardial infarction or stroke within past year

• Significant cognitive impairment, including:

known dementia diagnosis or a Mini-Mental State Examination exam score <24

• Progressive, degenerative neurologic disease (e.g., Parkinson's Disease, multiple sclerosis, ALS)

• Severe rheumatologic or orthopedic diseases (e.g., awaiting joint replacement, active inflammatory disease)

• Severe pulmonary disease, requiring either steroid pills or injections or the use of supplemental oxygen

• Hip fracture, hip or knee replacement, or spinal surgery within past 4 mos.

• Other significant co-morbid conditions that would impair ability to participate in the exercise-based intervention

• Simultaneous participation in another intervention trial

Related Conditions & MeSH terms

• Aging

Intervention

Drug:
• Resveratrol
Dietary compound commonly found in grapes and red wine. Will be given in 250 mg/day and 1000 mg/day dosages
• Placebo
Vegetable-based cellulose

Behavioral:
• Exercise
Multi-modal exercise regimen, 3 days/week

Locations

Country	Name	City	State
United States	UAB Center for Exercise Medicine	Birmingham	Alabama

Sponsors (3)

Lead Sponsor	Collaborator
University of Florida	National Institute on Aging (NIA), University of Alabama at Birmingham

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Walking Speed	Walking speed is assessed by asking the participants to walk at their usual pace over a 4 m course. Participants are to stand with both feet touching the starting line and to start walking after a verbal command is given, and the time needed to complete the entire distance will be recorded. The faster of two walks will be used and changes between the groups at baseline and 12 weeks will be assessed.	Change at Baseline to 12 weeks
Secondary	Short Physical Performance Battery (SPPB).	Investigators will assess lower-extremity function by asking the participants to perform a series of tasks including: walking at their usual pace over a 4 m course, repeated chair stands, and a balance test. Each task is scored from 0 to 4, with 4 indicating best level of performance and 0 the inability to complete the test. A summary score (0-12) is then calculated. Higher score on the scale is reflective of higher function and lower score reflects lower functioning. Changes between the groups at baseline and 12 weeks will be assessed.	Change between baseline to 12 weeks
Secondary	Isokinetic Strength.	Isokinetic strength of the dominant limb will be assessed by a standard dynamometer and changes between the groups at baseline and 12 weeks will be assessed.	Change between baseline and 12 weeks
Secondary	6-minute Walk Test	Investigators will assess exercise capacity of participants using the six-minute (6-min) walk test to assess change in meters walked between the groups at baseline and 12 weeks.	Change between Baseline and 12 weeks
Secondary	Late-Life Function and Disability Instrument	The instrument includes 16 tasks representing a broad range of disability indicators that assesses both frequency of doing a task and perceived limitation. The instrument uses a scale from 0 to 100, with higher scores indicating higher levels of function.	Change at Baseline to 12 weeks